APT Medical

APT Medical AAQS

The The AAQS of APT Medical (688617.SS) as of Oct 21, 2026 is 6. In the previous year, The AAQS was 6.00 — a change of 0.00% (lower).

AAQS

6

YoY

0.00%

Last updated:

APT Medical has a current AAQS of 6.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock APT Medical in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The APT Medical AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
6.00 CNY
Jan 1, 2019
6.00 CNY
Jan 1, 2020
6.00 CNY
Jan 1, 2021
6.00 CNY
Jan 1, 2022
6.00 CNY
Jan 1, 2023
6.00 CNY
Jan 1, 2024
6.00 CNY
Jan 1, 2025
6.00 CNY
The APT Medical AAQS history
YEARAAQSYoY
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
6—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

APT Medical Stock analysis

What does APT Medical do? APT Medical Inc generates revenue through the research, development, production, and sale of electrophysiology, coronary access, and peripheral vascular intervention medical devices. The company offers electrophysiological electrode catheters, controllable radiofrequency ablation electrode catheters, and multichannel electrophysiological systems under its electrophysiology product line. Its coronary access segment includes guide wires, micro catheters, balloons, contrast guide wires, and catheters. Peripheral vascular intervention products address peripheral vascular diseases and are sold domestically and internationally. The firm also engages in original equipment manufacturer (OEM) business, producing products for other brands. Domestic and overseas markets are the primary sales channels for all product segments. The company's electrophysiology products target healthcare providers specializing in cardiac procedures, while coronary access devices serve interventional cardiologists and vascular surgeons. Peripheral vascular intervention solutions are marketed to hospitals and clinics treating vascular conditions. OEM partnerships allow APT Medical to supply components to other medical device manufacturers without direct branding. These segments collectively drive revenue through direct sales to healthcare institutions and international distributors. APT Medical Inc's product portfolio includes electrophysiological systems and coronary access tools that cater to specific medical specialties. The firm's peripheral vascular intervention products are designed for treating conditions like peripheral artery disease. OEM business contributes to revenue by manufacturing components for other companies' branded products. Domestic market sales and overseas distribution networks form the core of the company's commercial strategy, with no mention of specific customer names or financial figures beyond the employee count. APT Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about APT Medical stock

The AAQS of APT Medical is 6 in 2025.

On Eulerpool you can find the complete historical development of The AAQS APT Medical since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — APT Medical

All Key Metrics — APT Medical